Metro Inc. (MRUN) Q3 2026 Earnings Report

The quarter shows a mix of clear operational headwinds and resilient long-term growth drivers. Near-term performance was materially affected by a labour strike that erased margin and profit and pressured same-store sales and EBITDA margins. Offsetting factors include strong pharmacy momentum (prescription growth, GLP-1 adoption), robust e-commerce growth (+16.3%), active network optimization with expected medium-term benefits (~$15M after-tax annually), continued retail expansion and a sizable share buyback program. Given the significant but (management describes) temporary strike-related impact alongside credible actions to improve network efficiency and long‑term growth in pharmacy and e-commerce, the positives and negatives are roughly balanced.

The company said Q3 adjusted EPS was $1.24 (within prior guidance) but expects Q4 to remain “significantly impacted” by the ongoing Laval strike—after four weeks food same‑store sales are down 1.5% and the strike is estimated to have an unfavorable after‑tax impact of ~$66 million (≈$0.32/share) and ~$90 million of lost profit and incremental direct costs in Q3; separately, Q3 included pretax restructuring of $25.7M and impairments of $32.1M (after‑tax adjustment $42.6M or $0.20/share) tied to network optimization. Management expects the network actions (including conversion of 10 Ontario stores and a Quebec e‑commerce model change) to be completed by end of FY2027 and to generate recurring after‑tax earnings of ~$15M by end of FY2028 (about half realized by end of FY2027), with required capital fitting within a $500–$550M annual CapEx envelope; proceeds of $90M from the Première Moisson facility sale are expected to close in Q4. They also guided that pharmacy momentum should continue (Q3 prescription sales +6.4%, pharmacy same‑store +4.8%) with GLP‑1s driving low‑teens volume and contribution growth, and that online sales growth (Q3 +16.3%) and discount conversions should improve store contribution beginning in FY2027.